Pharmaceutical

Meitheal gains rights to CONTEPO from Nabriva in North America

Meitheal Pharmaceuticals has gained rights to CONTEPO (fosfomycin for injection) from Nabriva Therapeutics for the North American region.

Jul 20, 2024 - 04:00
Meitheal gains rights to CONTEPO from Nabriva in North America
Meitheal Pharmaceuticals has gained rights to CONTEPO (fosfomycin for injection) from Nabriva Therapeutics for the North American region.
Read the original article

Tags:

Previous Article

Rona Therapeutics gains Series A+ funds for siRNA pipeline expansion

Next Article

EMA accepts Deciphera’s MAA cell tumour treatment for review

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: How drug pricing reforms are affecting Bayer’s investments

STAT+: How drug pricing reforms are affecting Bayer’s i...

Jun 20, 2023

Tired of ‘dead end’ approach, herpes patients mobilize to demand government action

Tired of ‘dead end’ approach, herpes patients mobilize ...

Apr 21, 2023

STAT+: UHS finance chief said company favors patients whose insurance pays more

STAT+: UHS finance chief said company favors patients w...

Jul 26, 2023